Lindsey O'Crump

Lindsey advises public and private companies on complex domestic and cross-border mergers and acquisitions, with deep experience across the life sciences, technology and healthcare sectors. She represents strategic acquirers, financial sponsors and venture-backed companies in their most significant transactions, including growth-driven acquisitions, joint ventures, carve-outs, option-to-acquire structures and milestone-based exits.

In the life sciences sector, Lindsey regularly counsels biotechnology, pharmaceutical, digital health and diagnostics companies on strategic exits, carve-outs and option-to-acquire transactions. Her experience includes representing Horizon Therapeutics in its $28 billion sale to Amgen, as well as advising clients, such as Jazz Pharmaceuticals and Travere Therapeutics, on high-stakes M&A transactions.

Lindsey’s representative matters:

Healthcare and life sciences M&A

• Candid Therapeutics in its agreement to acquire Rallybio through a reverse merger
• 35Pharma in its agreement to sell to GSK for $950 million
• RAPT Therapeutics in its sale to GSK for up to $2.2 billion
• Renalys Pharma in its sale to Chugai Pharmaceutical
• Capstan Therapeutics in its sale to AbbVie for $2.1 billion
• EsoBiotec in its sale to AstraZeneca for up to $1 billion
• Aculys Pharma in its sale to Viatris
• Inmagene Biopharmaceuticals in its reverse merger with Ikena Oncology to form ImageneBio
• Immunome in its acquisition of assets from Zentalis Pharmaceuticals
• Tvardi Therapeutics in its reverse merger with Cara Therapeutics
• Tempus AI in its acquisition of Ambry Genetics for $600 million
• Amolyt Pharma in its sale to AstraZeneca for up to $1.05 billion
• Nuvation Bio in its acquisition of AnHeart Therapeutics
• Landos Biopharma in its sale to AbbVie
• Propella Therapeutics in its sale to Astellas Pharma
• Jazz Pharmaceuticals in multiple transactions
• Travere Therapeutics in multiple transactions, including its sale
• Horizon Therapeutics in multiple transactions, including its sale
• Neogene Therapeutics in its sale to AstraZeneca for $320 million
• Kriya Therapeutics in its acquisition of Redpin Therapeutics
• Angion in its sale to Elicio Therapeutics in a reverse merger transaction
• ViaCyte in its sale to Vertex
• Turning Point Therapeutics in its sale to Bristol Myers Squibb for $4.1 billion
• CinCor in its sale to AstraZeneca for $1.8 billion
• Bionano Genomics in its acquisition of BioDiscovery
• Arena Pharmaceuticals in its option to acquire Aristea Therapeutics
• MannKind in its acquisition of QrumPharma
• Senomyx in its sale to Firmenich
• Retrophin in its acquisition of Orphan Technologies for $517 million
• Forbius in its sale to Bristol Myers Squibb for up to $1 billion
• Synthorx in its sale to Sanofi for $2.5 billion
• Genomatica in its acquisition of the REG Life Sciences division of Renewable Energy Group
• JCR Pharmaceuticals in its acquisition of ArmaGen
• Vical in its reverse merger with Brickell Biotech
• AmpliPhi in its reverse merger with C3J Therapeutics to form Armata Therapeutics

Technology M&A

• Transpose Data in its sale to Chainalysis
• Prodege in multiple transactions
• SendGrid in its sale to Twilio for $2 billion
• Tableau Software in its acquisition of Empirical Systems
• Approved Technologies in its sale to Credit Karma

Other sector M&A

• Heliogen in its sale to Zeo Energy
• ClosingCorp in its sale to CoreLogic
• Hanwha Q-Cells in its acquisition of Geli
• Fabric in its acquisition of RevCascade
• ticktBox in its sale to Screen Engine/ASI

Lindsey also brings significant experience guiding growth companies through complex corporate governance matters, public company readiness and acquisition-driven strategic planning.

A former co-chair of Cooley’s LGBTQ+ affinity group, Lindsey is committed to fostering inclusion and mentoring the next generation of lawyers.